- Home
- NEGG vs ADCT Comparison
NEGG vs ADCT Comparison
Compare NEGG & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- ADCT
- Stock Information
- Founded
- NEGG 2001
- ADCT 2011
- Country
- NEGG United States
- ADCT Switzerland
- Employees
- NEGG N/A
- ADCT N/A
- Industry
- NEGG Other Specialty Stores
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- NEGG Consumer Discretionary
- ADCT Health Care
- Exchange
- NEGG Nasdaq
- ADCT Nasdaq
- Market Cap
- NEGG 122.3M
- ADCT 241.0M
- IPO Year
- NEGG 2010
- ADCT 2020
- Fundamental
- Price
- NEGG $49.24
- ADCT $3.17
- Analyst Decision
- NEGG
- ADCT Strong Buy
- Analyst Count
- NEGG 0
- ADCT 6
- Target Price
- NEGG N/A
- ADCT $7.80
- AVG Volume (30 Days)
- NEGG 648.5K
- ADCT 918.9K
- Earning Date
- NEGG 08-28-2025
- ADCT 08-05-2025
- Dividend Yield
- NEGG N/A
- ADCT N/A
- EPS Growth
- NEGG N/A
- ADCT N/A
- EPS
- NEGG N/A
- ADCT N/A
- Revenue
- NEGG $1,235,576,000.00
- ADCT $75,817,000.00
- Revenue This Year
- NEGG N/A
- ADCT $11.75
- Revenue Next Year
- NEGG N/A
- ADCT $10.29
- P/E Ratio
- NEGG N/A
- ADCT N/A
- Revenue Growth
- NEGG N/A
- ADCT 10.49
- 52 Week Low
- NEGG $3.32
- ADCT $1.05
- 52 Week High
- NEGG $56.00
- ADCT $4.13
- Technical
- Relative Strength Index (RSI)
- NEGG 91.69
- ADCT 59.73
- Support Level
- NEGG $15.31
- ADCT $2.66
- Resistance Level
- NEGG $17.52
- ADCT $3.30
- Average True Range (ATR)
- NEGG 4.56
- ADCT 0.20
- MACD
- NEGG 2.70
- ADCT 0.01
- Stochastic Oscillator
- NEGG 85.35
- ADCT 90.00
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).